ERLOTINIB HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Erlotinib Hydrochloride patents expire, and what generic alternatives are available?
Erlotinib Hydrochloride is a drug marketed by Accord Hlthcare, Alembic, Apotex, Eugia Pharma, MSN, Natco Pharma Ltd, Rising, Shilpa, Sun Pharm, Teva Pharms Usa Inc, and Zydus Pharms. and is included in eleven NDAs.
The generic ingredient in ERLOTINIB HYDROCHLORIDE is erlotinib hydrochloride. There are twenty-five drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the erlotinib hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Erlotinib Hydrochloride
A generic version of ERLOTINIB HYDROCHLORIDE was approved as erlotinib hydrochloride by RISING on June 11th, 2014.
Summary for ERLOTINIB HYDROCHLORIDE
Recent Clinical Trials for ERLOTINIB HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
MedSIR | Phase 2 |
Asan Medical Center | Phase 2 |
Boryung Pharmaceutical Co., Ltd | Phase 2 |
Pharmacology for ERLOTINIB HYDROCHLORIDE
Drug Class | Kinase Inhibitor |
Mechanism of Action | Protein Kinase Inhibitors |
Medical Subject Heading (MeSH) Categories for ERLOTINIB HYDROCHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for ERLOTINIB HYDROCHLORIDE
Paragraph IV (Patent) Challenges for ERLOTINIB HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
TARCEVA | Tablets | erlotinib hydrochloride | 25 mg | 021743 | 1 | 2008-11-18 |